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Abstract
New developments in the study of brain are among the most exciting frontiers of
contemporary neuroscientific research for the clinical practitioner. Increasing knowl-
edge of neurocomplications and of their discrete localization in the various regions of
brain permits new modes of pharmacological management of some major neurological
disorders like autism. The research work reported in this scheme is undertaken with an
objective to explore the potential molecular targets (AC/cAMP/PKA/CREB) for the
development of newer therapeutics strategies (forskolin) for the management of neuro-
logical disorders and associated symptoms. Studies aimed at addressing these questions
have fallen into two main categories: in-vivo behavioral paradigms and in-vitro differ-
entiation biochemical, morphological and histopathological analysis. Therefore, first
time, we aim to gather the propensity of mitochondrial cofactors, neuropathological
mechanisms and various diagnostic methods to explore the clinical therapeutic strate-
gies to ameliorate the neurodevelopmental disorder autism.
Keywords: neurodegeneration, autism, mitochondrial dysfunction, adenylyl cyclase,
forskolin
1. Introduction
Neurological disorders are a heterogeneous group of diseases of the nervous system having
different etiologies. They represent illnesses of the selective regions of the brain and nervous
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tissues which control vital physiological functions such as learning and memory, posture and
coordination of movements of nerves/muscles [1]. A variety of CNS disorders including
Alzheimer’s disease (AD), Parkinson’s disease, Huntington’s disease, amyotrophic lateral
sclerosis (ALS), autism spectrum disorders, brain abscess, multiple sclerosis, spinal cord injury,
and cerebral stroke, traumatic brain injury are characterized primarily by neurodegeneration
and neuroinflammation [2].
Intracellular molecules also known as secondary messengers such as cyclic nucleotides i.e.
cAMP and cGMP play a critical role in neuronal signaling and synaptic plasticity by activation
of several pathways like cAMP/PKA/CREB, cGMP/PKG/CREB and factors like brain-derived
neurotrophic factor (BDNF) [3], semaphorins [4], netrin-1&16 [5], nerve growth factor (NGF)
[6], Neurotrophins 3,4,5-inhibitory factors associated with myelin and myelin associated gly-
coprotein [MAG] [7]. These pathways and factors are well known to help in neuronal survival,
neurogenesis and protect neurons from injury [8].
Elevation of cAMP causes both short- and long-term increase in synaptic strength [9] and
stimulates cholinergic neuronal cells to release acetylcholine [10]. But, the levels of cAMP and
cGMP are reported to be decreased in neuropathological conditions including cerebral stroke
and AD [11].
It has been reported that cerebral ischemia-induced energy failure also leads to reduction in
the levels of key signaling molecules such as cAMP and cGMP and results in disruption of
cAMP/PKA/CREB [11] and cGMP/PKG/CREB signaling pathways [12]. On the other hand it
had been reported to impair hippocampal long-term potentiation (LTP), a neurophysiological
correlate of memory [13], by inhibiting the activation of both cAMP/PKA/CREB [14] as well as
cGMP/PKG/CREB pathways in ICH pathology [15]. The pyramidal CA1 neurons of hippo-
campus, involved in learning and memory become vulnerable target in cerebral stroke [16].
Further, cAMP or cGMP dependent CREB phosphorylation has too been reported to induce
long term memory (LTP) [17] and inhibit apoptotic and necrotic cell death [18].
CREB is a transcriptional factor responsible for synthesis of proteins which are important for
the growth and development of synaptic connections and increase in synaptic strength [19].
Thus, agents that enhance cAMP/PKA/CREB &cGMP/PKG/CREB pathways have potential
for the treatment of stroke [73], AD and other neurological diseases [20]. cAMP and cGMP
mediate signaling of several neurotransmitters including serotonin, acetylcholine, glutamate
and dopamine, which play important role in cognitive functioning [21]. The activation of the
cAMP-dependent protein kinase [PKA] significantly inhibits TNF-α [22] and inducible nitric
oxide synthase [iNOS] in astrocytes and macrophages [23] which are implicated in
neuroinflammation [22] and oxidative stress, respectively [24]. cAMP system is closely
involved in the regulation of BDNF expression too [25] which play important role in neuro-
nal survival [3], synaptic plasticity [26], learning and memory [27]. Further elevation of
cAMP and cGMP levels is known to restore the energy levels [28], reduce excitotoxic damage
[29], prevent Aβ-mediated neurotoxicity [14], enhance biosynthesis and release of neuro-
transmitters [22], inhibit apoptotic and necrotic cell death [30] leading to improvement in
cognitive functioning [31]. Central administration of cAMP and cGMP has been reported to
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enhance neuronal survival [32] and memory performance [31]. In view of the above, the
enhancement and prolongation of cAMP and cGMP signaling can thus be helpful in dealing
with neurodegenerative disorders including ICH. This can be accomplished by activating the
adenylyl cyclase enzyme, which metabolizes these cyclic nucleotides. Forskolin a major
diterpenoid isolated from the roots of Coleus forskohlii directly activates the enzyme adenylyl
cyclase, thereby increasing the intracellular level of cAMP and leading to various physiolog-
ical effects.
Despite substantial research into neuroprotection, treatment options are still limited to sup-
portive care and the management of complications. Currently available drugs provide symp-
tomatic relief but do not stop progression of disease. Thus, the development of new
therapeutic strategies remains an unmet medical need. Failure of current drug therapy may
be due to their action at only one of the many neurotransmitters involved [33] or their inability
to up regulate signaling messengers reported to have important role in neuronal excitability
[34], neurotransmitter biosynthesis and release [35], neuronal growth and differentiation [30],
synaptic plasticity and cognitive functioning [36].
2. Experimental animal model of PPA-induced neurotoxicity
Administration of PPA to rodents, results in CNS lesions that selectively target right lateral
ventricle associated within striatum, cortex, cerebellum, hippocampus, amygdala recapitulat-
ing the regional and neuronal specificity of pathologic events especially in autism [37]. The
mitochondrial toxin PPA interferes with the conversion of succinate to fumarate in TCA cycle,
responsible for the generation of FADH2 utilized in the complex-II in mitochondrial electron
transport chain (ETC) by which it direct inhibits the activity of the mitochondrial metabolic
enzyme succinate dehydrogenase and reduced the definite amount of NADH where it con-
sumed in complex-I with the help of an enzyme complex-I (NADPH oxidase) as well as
involve in the dysregulation of complex-IV (cytochrome c oxidase), is the final protein complex
in the ETC helping to establish a transmembrane difference of proton electrochemical potential
that the complex-V (ATP synthase) then uses to synthesize ATP [38].PPA has now become an
experimental tool to study neuronal susceptibility and motor phenotypes that are characteris-
tic of autism (Figure 1) [39].
In rats, PPA-induced lesions in brain region that are associated with elevated lactate levels
resulted in increased NMDA-receptor binding. PPA toxicity arises from secondary excitotoxic
mechanisms, whereby energy depletion within vulnerable neurons facilitates abnormal activa-
tion of NMDA receptors and subsequent Ca2+ influx [40]. Stimulating energy generation by
administering creatine markedly attenuates PPA toxicity and ameliorates lesion volume, lac-
tate production and ATP depletion in PPA-treated rats [41]. Numerous reports assert that PPA
toxicity is associated with increased oxidative damage within the CNS. The involvement of
impairments in intrinsic anti-oxidant protection pathways after PPA administration is further
supported by observations of reduced glutathione (GSH) levels in autistic brain [42].
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2.1. Propionic acid and autism
Propionic acid (PPA) is a short chain fatty acid formed endogenously in the human body as an
intermediate of fatty acid metabolism and a metabolic end product of enteric gut micro biota
such as clostridia and propionic bacteria [43–46]. MacFabe et al. and Shultz et al. have demon-
strated that PPA intraventricularly infused to rats provides a suitable animal model to study
autism. Being a weak organic acid, PPA exists in ionized and nonionized forms at physiological
pH allowing it to readily cross lipid membranes, including the gut-blood and blood-brain
barriers. PPA and other short-chain fatty acids (i.e., butyrate and acetate), affect diverse physio-
logical processes such as cell signaling, neurotransmitter synthesis and release, mitochondrial
Figure 1. PPA-induced neurotoxicity; selective mitochondrial inhibition.
Figure 2. Intraventricular injection of PPA-inducing neurotoxic effect in mitochondrial respiratory chain (ETC).
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function, lipid metabolism, immune functions, gap junctional gating, and modulation of gene
expression through DNA methylation and histone acetylation [47]. Initial studies using this
rodent model revealed that repeated brief infusions of PPA into the lateral cerebral ventricles
(i.e., AP 1.3 mm, ML 1.8 mm, and DV 3.0 mm) of adult rats produced behavioral, biochemical,
electrophysiological and neuropathological effects consistent with those seen in autism [43]. PPA
through oxidative mechanisms inhibits Na+/K+ ATPase and increases glutamate receptor sensi-
tivity which can enhance neural depolarization leading to neural hyper excitability in brain
regions linked to locomotor activity (Figure 2).
Mitochondrial dysfunction has been well established to occur and play an important role in the
pathogenesis of autism [48]. Preliminary magnetic resonance spectroscopy studies showed
decreased synthesis of ATP and a disturbance of energy metabolism in the brain of individuals
with autism. PPA is also capable of altering dopamine, serotonin, GABA and glutamate
systems in a manner similar to that observed in autism [49].
3. List of proposed parameters can be evaluated on the basis of behavioral
and biochemical alterations in neurotoxic experimental animal models of
autism
Proposed experimental design of propionic acid-induced behavioral and biochemical estima-
tions (Figure 3)
1. Measurement of body weight
2. Measurement of brain weight
3. Behavioral parameters
Spatial navigation task in Morris water maze, spontaneous locomotor activity, string test for
grip strength, elevated plus maze test, beam crossing task, force swim test, rota rod apparatus
4. Estimation of biochemical parameters
Preparation of homogenate, estimation of biochemical parameters in serum and tissue homogenate
such as protein estimation, lactate dehydrogenase (LDH) assay, estimation of malondialdehyde
(MDA) levels, glutathione levels, superoxide dismutase (SOD) activity, catalase activity, acetyl
cholinesterase (AChE) levels, determination of protein carbonyl (PC), nitrite levels
5. Estimation of biochemical parameters in serum and urine
Estimation of total urea, estimation of uric acid, estimation of biochemical parameters in tissue
homogenate for mitochondrial complex activity
6. Preparation of crude mitochondrial fraction from rat whole brain homogenate
Complex-1 activity (NADPH dehydrogenase), complex-II activity (succinate dehydrogenase/
SDH), complex IV activity (cytochrome oxidase), complex-V activity (ATP synthase)
7. Estimation of biochemical parameters in serum
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Estimation of complete blood count (CBC) such as determination of different hematological
parameters, such as red blood cells (RBC), white blood cells (WBCs), hemoglobin (HB), hemat-
ocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean
corpuscular hemoglobin concentration (MCHC), red blood cell distribution width (RDW),
neutrophils%, lymphocytes%, monocytes%, eosinophil’s%, basophils%, mean platelet volume
(MPV), platelet distribution width (PDW)%, plateletcrit (PCT)% and platelets (PLTs) was
measured in rat serum or blood sample
8. Miscellaneous
Estimation of blood glucose levels, triglycerides levels, total cholesterol levels, serum C-reactive
protein (CRP) levels
9. Inflammatory parameters in tissue homogenate-enzyme-linked immunosorbent assay (ELISA)
Estimation of TNF-α, interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-10 (IL-10)
10. Estimation of biochemical parameters in urine
Urine output, urine dipstick test
11. Histopathological and morphological sections studies
12. Immunohistochemistry
4. Future perspectives and treatment approach
Phytochemicals drugs have been used since ancient times as medicines for treatment of a range
of diseases. Medicinal plants have played a key role in world health. In spite of the great
Figure 3. Proposed experimental design: propionic acid-induced behavioral and biochemical estimations.
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advances observed in modern medicine in recent decades, plants still make an important
contribution to health care. Medicinal plants are distributed worldwide, but they are most
abundant in tropical countries. Over the past decade, interest in drugs derived from higher
plants, especially the phototherapeutic ones, has increased expressively. It is estimated that
about 25% of all modern medicines are directly or indirectly derived from higher plants.
Phytomedicines are standardized herbal preparation consisting of complex mixtures of one or
more plants which are used in most countries for the management of various diseases. Other
characteristics of phytochemicals are their wide therapeutic use and great acceptance by the
population. In contrast to modern medicines, phytochemicals are frequently used to treat
chronic diseases. Phytochemicals are normally marketed as standardized preparations in the
form of liquid, solid, or various preparations. Compared with well-defined synthetic drugs,
phytochemicals exhibit some marked differences, namely:
• The empirical use in folk medicine is a very important characteristic.
• They have a wide range of therapeutic use and are suitable for chronic treatments.
• The occurrence of undesirable side effects seems to be less frequent with herbal medicines,
but well-controlled randomized clinical trials have revealed that they also exist.
• They usually cost less than synthetic drugs
5. Forskolin (Coleus forskohlii)
Coleus forskohlii known as phashana bedi (Telugu) a medicinal plant found in the Indian
subcontinent is widely used in the Indian system of medicine. Forskolin (FSK) (also known as
Colonels) is labdane diterpene that is obtained from the tuberous roots of Coleus forskohlii,
which belongs to the family of Lamiaceae. Coleus Forskohlii is one of the world’s most
researched plant in which FSK is believed to be the plant’s most active constituent. C. forskohlii
has been used as an important folk medicine in India. C. forskohlii is a perennial herb and
grows wild in arid and semi-arid regions of India, Nepal and Thailand; the roots have long
been used in Ayurvedic medicine [50]. In traditional medicine, C. forskohlii is commonly used
in different countries for various health disorders including cardiovascular diseases, hyperten-
sion, asthma, glaucoma and Alzheimer’s disease. Its further use in promoting lean body mass,
treating mood disorders and its anticancer activities is well known.
6. Medicinal properties of forskolin
Traditionally, the roots have been used as condiments in pickles, for preparation of pickles.
Forskolin has positive effect against a wide range of conditions such as asthma, glaucoma,
hypertension, hair loss, cancer, and obesity [51]. C. forskohlii extract (standardized to contain
95% forskolin) is potentially useful in skin care formulations, particularly as a conditioning
age. In traditional Indian systems of medicine, the roots of C. forskohlii are used as a tonic.
Other therapeutically relevant properties include anthelmintic action and efficacy in the
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management of skin infections and eruptions. The plant is also used traditionally in veterinary
practice (Table 1). Essential oil in tubers of this plant has potential uses in food flavoring industry
and can be used as an antimicrobial agent and has very attractive and delicate odor with spicy
note. A labdane diterpenoid is considered the active secondary metabolite because of its ability
to activate the enzyme adenylyl cyclase (Ac) thereby increasing the intracellular level of cAMP
and leading to various physiological effects [52]. FSK is shown to exert a 6–400 fold increase in
levels of cAMP. Cyclic AMP is a “second messenger” hormone signaling system as its synthesis
triggers the action of various hormones, enzymes and other biological activities that have
profound effects on local cells, as well as systemic effects, in some instances, on the entire body
[53]. FSK by passes the adrenoreceptors, increasing cAMP levels directly, thereby stimulating
lipolysis. FSK has also been shown to counteract the decreased response of fat cells to epineph-
rine, associated with aging. FSK also accelerates lipolysis through the activation of hormone-
sensitive lipase [54]. It is primarily via the increased synthesis of cyclic AMP that C. Forskohlii
may exert its medicinal influences on a significant number of common health conditions.
S.No. Pharmacological activity Mechanism of action Ref. No
i. Anti-depressant FSK stimulated AC activity in rat brain and leads to
enhancement of the coupling between stimulatory GTP-
binding protein (G protein) and AC catalytic molecules
FSK stimulates AC and regulates brain-derived neurotrophic
factor (BDNF) and TrkB expression in the rat brain
92
ii. Anti-Alzheimer’s FSK-induced abipolar neuron-like cell morphology and it
enables neurogenin-2 (Ngn2) to convert human fibroblasts
into cholinergic neurons
Neuronal differentiation of adult rat neural progenitor cells
(NCP’s) was achieved
93
iii. Anti-cancer Restoration of PP2A activity with forskolin that inhibit Akt
and ERK activity and block proliferation and induce caspase-
dependent apoptosis in AML cell lines.
Forskolin inhibited the in-vivo leukemogenesis of imatinib
sensitive and resistant BCR/ABL+ 32Dcl3 cells in mice
94
iv. Antispasmodic activity increase of cAMP inhibit cramping or smooth muscle
contraction
95
v. Anti-Glaucoma Stimulates Adenylate cyclase which stimulates the ciliary
epithelium to produce cyclic adenosine monophosphate
(cAMP) that results in decreased aqueous humor inflow
there by decrease in IOP
Reduction of intra ocular pressure
96
vi. Cardioprotective amelioration of
Mitochondrial dysfunction in
cardiomyopathy
It reduces diastolic blood pressure without increasing
myocardial oxygen consumption.
Reduction of INa (cardiac Na + current) and overproduction
of mitochondrial ROS in deoxycorticosterone acetate
(DOCA) mouse myocytes by activating PKA and PKC
97
vii. Anti-asthmatic Forskolin activation of cAMP inhibits human basophil and
mast cell degranulation, resulting in subsequent
bronchodilation
98
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7. FSK and brain
7.1. FSK-binding sites
3H-forskolin has, for example, been found to bind to both a high and a low affinity site in rat
brain membranes [55] and the capacity of the high affinity forskolin-binding site has been
shown to be increased by the activation of N-proteins by guanine nucleotides [56]. High
affinity [3H] FSK-binding sites have been mapped autoradiographically in rat brain area such
as caudate-putamen, nucleus accumbens, olfactory tubercle, globus pallidus, substantia nigra
and the hilus of the area dentata [57] and exhibit a markedly heterogeneous distribution.
S.No. Pharmacological activity Mechanism of action Ref. No
viii. Anti-psoriasis Decreased cGMP levels that are associated with cell
proliferation and thus decrease cell division.
Normalizing the cAMP /cGMP ratio
99
ix. Hepatoprotective activity Repair of hepatic tissue damage, normalization of
inflammatory hepatic and necrosis
Forskolin increases cAMP accumulation, and therefore
stimulates lipolysis.
100
x. Anti-inflammatory Reduction in the level of Interleukin-1β, 6 and 8
Overexpression of TANK-binding kinase 1 (TBK1) reduced
phosphorylation of hormone-sensitive lipase (HSL) in
response to FSK
Inhibit mast cell degranulation
101
xi. Anti-diabetic activity FSK predominantly decreased basal glucose in healthy rats
and attenuated the severity of hyperglycemia in diabetic rats
FSK increase intracellular cAMP, which, together with the
increase in ATP, enhance the priming of insulin granules
102
xii. Anti-platelet aggregation Antagonizes the action of platelet-activating factor (PAF).
Reduction in the extent of platelet aggregation
Induced a partial deaggregation of ADP- or collagen-
aggregated human platelets
103
xiii. Inhibition
of human neutrophil degranulation
Anti-histaminic activity
cAMP-mediated phosphodiesterase inhibition.
Reduction in the histamine release from human basophiles
and mast cells by modulating the release of mediators of the
immediate hypersensitivity reaction, through activation of
AC
104
xiv. Smooth muscle relaxant Increase both the cytosolic Ca2+ concentration and the
cytosolic NO concentration ([NO]c) in the endothelial cells
leads to cause vasodilatation
Increases uterine smooth muscle AC
105
xv. Hydrodynamic alterations in collecting
tubule
Anti-cystic fibrosis
FSK resulted in increase in osmotic water flux and hydraulic
conductivity of the rabbit cortical collecting tubule
FSK leads to cyst formation in culture media
106
Table 1. Pharmacological action of FSK.
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7.2. Role of FSK in brain
FSK may activate Ac by interacting with two sites, one which may be directly located on the
cyclase molecule, and the other which is associated with OJ somehow formed by the inter-
actions with the N, protein. FSK, a commonly used activator of Ac [55], elevates the
stimulation-induced release of several transmitters, such as acetylcholine, noradrenaline
and 5-hydrdoxytryptamine, from brain or synaptosomes and markedly increasing the rate
of conversion of ATP to cyclic AMP [58]. FSK directly reduces certain K + potassium
currents in addition to its action on Ac. cAMP could increase the apparent number of Na,
K-ATPase sites by either direct or indirect mechanisms. cAMP could increase the number of
Na, K-ATPase sites by increasing cell Na + or decreasing K + though there are reports of Na,
K-ATPase stimulation that may be independent of cation changes. FSK elevates electrically
evoked acetylcholine release in the hippocampus independently of Ac activation [58]. FSK
appears to provide a new clue for elucidating the physiological role of cAMP in the synaptic
transmission in the sympathetic ganglia. FSK exerts two opposite pharmacological actions
at the synapse, i.e. a facilitation of transmitter release at the presynaptic site and a depres-
sant action on nicotinic acetylcholine receptor at the postsynaptic site. FSK reduced the
amplitude shock stimulation of preganglionic nerve. FSK induces a reversible AChR desensiti-
zation at the junctional and extrajunctional regions in rat [59]. FSK, an activator of Ac, could
increase transmitter release presynaptically in CA1 neurons. FSK directly stimulates Ac and
thereby increases cyclic AMP activity, which is known to influence neurite outgrowth and
membrane trafficking in neurons. Increased cyclic AMP activity may have multiple effects on
cells including changing the direction of growing neurites [60] and increasing the density of
clathrin-coated pits and coated vesicles at plasma membranes coincident with an increased
synthesis of clathrin light chain. The cAMP effector system enhanced by FSK is involved in the
release of dopamine from dopaminergic nerve endings in the neostriatum [61]. FSK increased
dopamine formation in rat striatal slices, rat striatal synaptosomes, rat hypothalamic synapto-
somes and bovine retinal slices [62].
8. Neuroprotective action of FSK
8.1. FSK against neuroinflammation
An increase in intracellular cAMP levels through FSK to play an important role in modulating
the cytokine production. Intracellular cAMP has been reported to depress the accumulation of
tumor necrosis factor (TNF-α) an mRNA by inhibiting the transcriptional processes. Elevation of
intracellular cAMP levels induced by PDE inhibitors, FSK, prostaglandin E2, or cell-permeable
cAMP analogue also inhibited the secretion of IL-1b, whereas it increased IL-1b mRNA levels
from lipopolysaccharide-stimulated human monocytes. Although the regulatory modality of IL-
8 production by cAMP is still unclear and depends on the cell type, enhanced cAMP appears to
have favorable effects at least on airway cells by suppressing IL-8 production [63]. Therefore,
enhanced cAMP levels by have also FSK been recognized to reverse the increased pulmonary
microvascular permeability associated with ischemia reperfusion (Figure 4) [64].
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8.2. Forskolin against neurooxidation
Oxidative stress may play a role in the development and clinical manifestations of autism.
Both central and peripheral markers of oxidative stress have been reported in autism.
Peripheral markers have included lipid peroxidation levels. Increases in these markers cor-
related with loss of previously acquired language skills in autism. Furthermore, metabolic
markers of oxidative stress have been identified including abnormal levels of metabolites
signifying impaired methylation and increased oxidative stress in autism [65]. The oxidative
stress in autism may be caused by an imbalance between the generation of ROS and the
defense mechanism against ROS by antioxidants. An increase in reactive oxygen species
(ROS) results in damage to proteins, DNA, and lipids. Specifically, the interaction between
ROS and nitric oxide (NO) results in the nitration of tyrosine residues in proteins and can
alter protein conformation and function [66]. Oxidative DNA damage is also considered to
play an important role in the pathology of a number of diseases like Parkinson’s disease,
tardive dyskinesia, metal intoxication syndromes, Down’s syndrome, and possibly also in
schizophrenia, Huntington’s disease, and Alzheimer’s disease. Reactive oxygen species
including superoxide (O2.–), hydroxyl (.OH), hydrogen peroxide (H2O2), singlet oxygen
(1O2) and nitric oxide (NO•) can cause cellular injury when they are generated excessively
or the enzymatic and nonenzymatic antioxidant defense systems are impaired [67].
Figure 4. Neuroprotective action of forskolin-mediated AC/cAMP/PKA/CREB activation.
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Moreover, FSK-mediated cAMP/PKA/CREB activation were found to inhibit LPS- and
cytokine-mediated production of NO as well as the expression of iNOS, whereas compounds
(H-89 and (Rp)-cAMP) that decrease PKA activity stimulated the production of NO and the
expression of iNOS in rat primary astrocytes [68].
8.3. Forskolin against mitochondrial dysfunctioning
The brain is strongly dependent on the ATP production of the cell energy-producing organelle,
the mitochondrion. There is a large body of evidence involving mitochondrial dysfunctions in
ASD. Palmieri and Persico, regarding ASD, oxidative phosphorylation (OXPHOS) in the
mitochondrion requires at least 80 proteins, of which only 13 are encoded by the mtDNA,
while mitochondrial functioning has been estimated to need the participation of approxi-
mately 1500 nuclear genes. Mitochondrial dysfunction is present in the brains of individuals
with ASD and may play a role in its core cognitive and behavioral symptoms. Alternatively,
mitochondria can be damaged by endogenous stressors associated with ASD such as elevated
pro-inflammatory cytokines resulting from an activated immune system or other conditions
associated with oxidative stress. Oxidative stress may be a key link between mitochondrial
dysfunction and ASD as reactive oxygen species (ROS) generated from pro-oxidant environ-
mental toxicants and activated immune cells can result in mitochondrial dysfunction. Excess
production of free radicals or impaired antioxidant mechanisms may cause oxidative stress:
impaired mitochondrial function then leads to further oxidative stress and a vicious negative
cycle can ensue. Instead, abnormal functioning appears secondary to excessive Ca2+ levels.
Mitochondrial dysfunctioning caused depletion of ATP, that further decrease the level of
cAMP. Forskolin, increase in intracellular cAMP, through the phosphorylation of CREB which
perform neuroprotective functioning associate with mitochondrial dysfunctioning [69].
8.4. Forskolin against cognitive dysfunction
Autistic brain which may reflect enhanced cortical plasticity which is defined as the process of
microstructural construction of synapses occurring during development and the remodeling of
these synapses during learning [70]. Enhanced synaptic plasticity triggers a regional reorgani-
zation of brain functions that account for both the unique aspects of autism and its variability
[71]. Activation of cAMP/PKA has been mainly implicated in stimulating learning and mem-
ory. FSK activate cAMP/CREB in hippocampal region [72].
8.5. Possible involvement of FSK in PPA-induced autism
Summarizing the whole information given above, FSK confirmed a versatile role in autism
where it activates the AC/cAMP-mediated PKA/CREB activation. Moreover, on other side FSK
act as a co-activator in brain that follows the GS pathway through the activation of D1 receptor.
There is least availability of selective AC activation and so far only limited reports suggest
beneficial effect of FSK in neurodegeneration animal model.
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9. Conclusion
In conclusion, the current study strongly confirms that the administration of propionic acid
induces brain lesions that are similar to the behavioral, histological, morphological, biochemical,
neurochemical, and pathological features of autism. After Chronic administration of propionic
acid in the rats as proven by motor dysfunctions, biochemical and neurochemical alternations.
The literature finding in the current study reveals that adenylyl cyclase activator, that is, FSK-
mediated cAMP/CREB activation, might be a unique platform for the prevention of neurodegen-
erative diseases. Thus in conclusion, neuroprotective and neuro restoration effects of FSKmay be
due to favorable modulation of CREB-mediated signaling. The involvement of cAMP/PKA/CREB
pathway, anti-oxidant, anti-inflammatory and neuroprotective effect of test drug FSKmay be the
possible mechanisms at least in part underlying the observed effects (Figure 4).
Furthermore, with cAMP/PKA/CREB signaling in regulation of neuronal functioning, the
future studies can be designed to investigate the protective and therapeutic potency of
forskolin in animal models of brain hemorrhage, Huntington’s disease and Parkinson’s disease
and to find out if cAMP-mediated CREB pathway is equally implicated in the disease patho-
genesis or progression. So, now we can finally conclude the significant mitochondrial restor-
ative effects of the FSK may be due to showing its improved motor and cognitive functions as
well as to restore the energy levels and antioxidant and anti-inflammatory defense system.
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